WuXi Biologics is a leading global contract developer and manufacturer (CDMO) of biologic drugs. It trades on Hong Kong Stock Exchange under the ticker 2269.HK, in the Biotechnology Services sector.
Key Facts
| Item | Details |
|---|---|
| Ticker | 2269.HK |
| Exchange | Hong Kong Stock Exchange (2269.HK) |
| Sector | Biotechnology Services |
| Headquarters | Wuxi, China |
Bull Case & Risks
Bull Case
- A leading global biologics CDMO
- A large, growing project pipeline
- Scale and capacity expansion
Risks
- US BIOSECURE-Act and geopolitical risk
- Biotech-funding cyclicality
Outlook
WuXi Biologics is a top global biologics CDMO with a large pipeline, but its shares hinge on US legislative and geopolitical risk around Chinese drug services.
Educational information only, not investment advice. Stocks carry risk including possible loss of principal; past performance does not guarantee future results.